Chemotherapy

February 7, 2024
A 3D illustration of an antibody molecule, depicted in purple and orange, with orange spheres marking specific points and orange lines extending outward for emphasis.
Published by TDP on February 7, 2024
Categories

Unlocking the Potential of Enhertu: A Revolutionary Advance in Targeted Cancer Therapy

The development of Enhertu represents a significant advancement in targeted cancer therapy, offering new hope for patients with limited treatment options. Enhertu, also known as trastuzumab deruxtecan, is an innovative antibody-drug conjugate (ADC) designed to target HER2-positive cancers, which are associated with aggressive growth and poor prognosis in various cancer types, including breast and gastric cancers
Do you like it?11
0 Read more
January 22, 2024
A close-up of a Pluvicto prescription label and vial, showing details such as dosage, storage instructions, and ingredient information for the intravenous medication.
Published by TDP on January 22, 2024
Categories

Pluvicto: Most Asked Questions

"for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy."
Do you like it?26
0 Read more
January 19, 2024
A doctor wearing a white coat and stethoscope examines a chest X-ray image, standing in a bright medical office.
Published by TDP on January 19, 2024
Categories

Why Atezolizumab and Chemotherapy Should Be Used with Caution in Real-World SCLC Population

Atezolizumab, a programmed death-ligand 1 (PD-L1) inhibitor, has shown promising results in clinical trials when combined with chemotherapy for the treatment of extensive-stage small cell lung cancer (ES-SCLC). However, a real-world evaluation of atezolizumab plus platinum-etoposide chemotherapy in patients with ES-SCLC in Canada raises important considerations regarding its use.
Do you like it?33
0 Read more
123
Understanding Chemotherapy
This website uses cookies to improve your experience. By using this website you agree to our Cookie Policy.
Read more